These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 29959570)

  • 41. Expression of FOXM1 and related proteins in breast cancer molecular subtypes.
    Lee JJ; Lee HJ; Son BH; Kim SB; Ahn JH; Ahn SD; Cho EY; Gong G
    Int J Exp Pathol; 2016 Apr; 97(2):170-7. PubMed ID: 27277416
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer.
    Christensen E; Birkenkamp-Demtröder K; Nordentoft I; Høyer S; van der Keur K; van Kessel K; Zwarthoff E; Agerbæk M; Ørntoft TF; Jensen JB; Dyrskjøt L
    Eur Urol; 2017 Jun; 71(6):961-969. PubMed ID: 28069289
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impaired estimated glomerular filtration rate is a significant predictor for non-muscle-invasive bladder cancer recurrence and progression--introducing a novel prognostic model for bladder cancer recurrence.
    Rausch S; Hennenlotter J; Todenhöfer T; Aufderklamm S; Schwentner C; Sievert KD; Stenzl A; Gakis G
    Urol Oncol; 2014 Nov; 32(8):1178-83. PubMed ID: 24962661
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Expression of FoxM1 is required for the proliferation of medulloblastoma cells and indicates worse survival of patients.
    Priller M; Pöschl J; Abrão L; von Bueren AO; Cho YJ; Rutkowski S; Kretzschmar HA; Schüller U
    Clin Cancer Res; 2011 Nov; 17(21):6791-801. PubMed ID: 21918172
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.
    Kim JS; Chae Y; Ha YS; Kim IY; Byun SS; Yun SJ; Kim WJ
    Clin Genitourin Cancer; 2012 Jun; 10(2):114-20. PubMed ID: 22382007
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical significance of CD44 variant 9 expression as a prognostic indicator in bladder cancer.
    Kobayashi K; Matsumoto H; Matsuyama H; Fujii N; Inoue R; Yamamoto Y; Nagao K
    Oncol Rep; 2016 Nov; 36(5):2852-2860. PubMed ID: 27599396
    [TBL] [Abstract][Full Text] [Related]  

  • 47. miR-221/222 cluster expression improves clinical stratification of non-muscle invasive bladder cancer (TaT1) patients' risk for short-term relapse and progression.
    Tsikrika FD; Avgeris M; Levis PK; Tokas T; Stravodimos K; Scorilas A
    Genes Chromosomes Cancer; 2018 Mar; 57(3):150-161. PubMed ID: 29181884
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy?
    Park J; Song C; Shin E; Hong JH; Kim CS; Ahn H
    Urol Oncol; 2013 Aug; 31(6):849-56. PubMed ID: 21782482
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Chronic kidney disease as an important risk factor for tumor recurrences, progression and overall survival in primary non-muscle-invasive bladder cancer.
    Li CE; Chien CS; Chuang YC; Chang YI; Tang HP; Kang CH
    Int Urol Nephrol; 2016 Jun; 48(6):993-9. PubMed ID: 26995008
    [TBL] [Abstract][Full Text] [Related]  

  • 50. FoxM1: Repurposing an oncogene as a biomarker.
    Nandi D; Cheema PS; Jaiswal N; Nag A
    Semin Cancer Biol; 2018 Oct; 52(Pt 1):74-84. PubMed ID: 28855104
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Assessment of CEP55, PLK1 and FOXM1 expression in patients with bladder cancer in comparison with healthy individuals.
    Seyedabadi S; Saidijam M; Najafi R; Mousavi-Bahar SH; Jafari M; MohammadGanji S; Mahdavinezhad A
    Cancer Invest; 2018; 36(8):407-414. PubMed ID: 30277841
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Oncological outcomes of a single but extensive transurethral resection followed by appropriate intra-vesical instillation therapy for newly diagnosed non-muscle-invasive bladder cancer.
    Koie T; Ohyama C; Hosogoe S; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Mori K
    Int Urol Nephrol; 2015 Sep; 47(9):1509-14. PubMed ID: 26149637
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Presence of Concomitant Non-muscle-invasive Bladder Cancer in Chinese Patients with Upper Tract Urothelial Carcinoma: Risk Factors, Characteristics, and Predictive Value.
    Fang D; Zhang L; Li X; Yu W; Singla N; Zhao G; Xiong G; Song Y; He Q; He Z; Zhou L
    Ann Surg Oncol; 2015 Aug; 22(8):2789-98. PubMed ID: 25564161
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The role of oncostatin M receptor gene polymorphisms in bladder cancer.
    Deng S; He SY; Zhao P; Zhang P
    World J Surg Oncol; 2019 Feb; 17(1):30. PubMed ID: 30755233
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prognostic significance of FOXM1 expression and antitumor effect of FOXM1 inhibition in synovial sarcomas.
    Maekawa A; Kohashi K; Kuda M; Iura K; Ishii T; Endo M; Nakatsura T; Iwamoto Y; Oda Y
    BMC Cancer; 2016 Jul; 16():511. PubMed ID: 27439614
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of Occupational Exposures and Genetic Polymorphisms on Recurrence and Progression of Non-Muscle-Invasive Bladder Cancer.
    Carta A; Pavanello S; Mastrangelo G; Fedeli U; Arici C; Porru S
    Int J Environ Res Public Health; 2018 Jul; 15(8):. PubMed ID: 30042310
    [No Abstract]   [Full Text] [Related]  

  • 57. Prognostic Impact of a 12-gene Progression Score in Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Validation Study.
    Dyrskjøt L; Reinert T; Algaba F; Christensen E; Nieboer D; Hermann GG; Mogensen K; Beukers W; Marquez M; Segersten U; Høyer S; Ulhøi BP; Hartmann A; Stöhr R; Wach S; Nawroth R; Schwamborn K; Tulic C; Simic T; Junker K; Harving N; Petersen AC; Jensen JB; Keck B; Grimm MO; Horstmann M; Maurer T; Steyerberg EW; Zwarthoff EC; Real FX; Malats N; Malmström PU; Ørntoft TF
    Eur Urol; 2017 Sep; 72(3):461-469. PubMed ID: 28583312
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic factors of 'high-grade' Ta bladder cancers according to the WHO 2004 classification: are these equivalent to 'high-risk' non-muscle-invasive bladder cancer?
    Gontero P; Gillo A; Fiorito C; Oderda M; Pacchioni D; Casetta G; Peraldo F; Zitella A; Tizzani A; Ricceri F
    Urol Int; 2014; 92(2):136-42. PubMed ID: 24080613
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Quantitative genome-wide methylation analysis of high-grade non-muscle invasive bladder cancer.
    Kitchen MO; Bryan RT; Emes RD; Glossop JR; Luscombe C; Cheng KK; Zeegers MP; James ND; Devall AJ; Mein CA; Gommersall L; Fryer AA; Farrell WE
    Epigenetics; 2016 Mar; 11(3):237-46. PubMed ID: 26929985
    [TBL] [Abstract][Full Text] [Related]  

  • 60. MiR-216b inhibits cell proliferation by targeting FOXM1 in cervical cancer cells and is associated with better prognosis.
    He S; Liao B; Deng Y; Su C; Tuo J; Liu J; Yao S; Xu L
    BMC Cancer; 2017 Oct; 17(1):673. PubMed ID: 28978307
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.